Navigation Links
New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
Date:11/14/2011

l,(10) which has been used in the previous trials of anticoagulation for stroke prevention in patients with AFib.(10) A PROBE design may reflect the differences in the management of warfarin and dabigatran in clinical practice.(10)

The primary endpoint of the trial was incidence of stroke (including hemorrhagic) and systemic embolism.(10) Safety endpoints included bleeding events (major and minor), intracerebral hemorrhage, other intracranial hemorrhage, elevations in liver transaminases, bilirubin and hepatic dysfunction and other adverse events.(10)

In the RE-LY trial, all clinical outcomes were adjudicated in a blinded manner to assess outcomes for each treatment.(10)  

About Pradaxa® (dabigatran etexilate) Capsules

Indications and Usage

Pradaxa® (dabigatran etexilate mesylate) capsules is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

IMPORTANT SAFETY INFORMATION ABOUT PRADAXA

CONTRAINDICATIONS

PRADAXA is contraindicated in patients with active pathological bleeding and patients with a known serious hypersensitivity reaction (e.g., anaphylactic reaction or anaphylactic shock) to PRADAXA.

WARNINGS AND PRECAUTIONS

Risk of Bleeding

PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Risk factors for bleeding include:

- Medications that increase the risk of bleeding in general (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs)

- Labor and delivery

Promptly evaluate any signs or symptoms of blood loss, such as a drop in hemoglobin and/or hematocrit or hypotension. Consider evaluation of renal function. Discontinue PRADAXA in patients with active pathological bleeding.

Temporary Discontinuation of PRADAXA

Discontinuing
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Clinilabs will Conduct Phase 1 Trial Using QTinno®
3. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
6. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
7. Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
8. Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
9. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
10. Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
11. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Nashville Fertility ... was elected treasurer for the American Society for Reproductive ... knowledge and research in reproductive medicine. In his ... seat on the executive board and will have a ... Dr. Hill has actively supported ASRM since 1984 when ...
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/22/2014)... 22, 2014 The Center for ... of technical training across the life sciences industry, has ... (SCDM) to provide the organization's members with discounted ... access to the more than 350 sessions across 80 ... 10% off when registering for a public course ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... July 8 Cornerstone Therapeutics Inc. (Nasdaq: ... special meeting of its stockholders on August 27, 2009. ... will be asked to approve a series of amendments ... implement governance arrangements and provide Chiesi Farmaceutici SpA with ...
... SAN DIEGO, July 8 Biomatrica today announced that ... SampleMatrix room temperature storage technology to archive its DNA ... SampleMatrix technology in place of ultra-low-temperature freezers for the ... SMGF will move its collection of previously archived samples ...
... Researchers at Cellular Dynamics ... pluripotent stem cells, which have the ability to generate all ... ordinary human blood samples. This significant breakthrough provides a readily ... samples in storage at blood repositories and healthcare institutions worldwide. ...
Cached Biology Technology:Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 2Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 3Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 4Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 5Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatrica's Room Temperature Storage 2Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatrica's Room Temperature Storage 3Cellular Dynamics International Reprograms Blood Cells into Stem Cells 2
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... has been shown to cause pain by exciting the ... and the hot, spicy ingredient in chili peppers, UCSF ... plants and animals have evolved the same molecular strategy ... specific receptor on sensory nerves. The research provides new ...
... hold promise for reducing the destruction of dopaminergic cells ... lost to the disease, scientists say. , Research ... Neuroscience shows a human neural stem cell transplant essentially ... normally rather than displaying the progressive loss of movement ...
... discovered that mutations in a gene known as SOS1 ... common childhood genetic disorder which occurs in one in ... stature, facial abnormalities, and learning disabilities, as well as ... Led by researchers at Harvard Medical School-Partners Healthcare ...
Cached Biology News:Tarantula venom and chili peppers target same pain sensor 2Transplanted brain cells hold promise for Parkinson's disease 2Transplanted brain cells hold promise for Parkinson's disease 3Study uncovers mutation responsible for Noonan Syndrome 2
Gentamicin sulfate, 5g...
E2F2 protein...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Biology Products: